Fotemustine
As of the edition of 20 October 2026, Fotemustine is a small molecule: marketed, first approved in 1989 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Muphoran
- First approved
- 14 April 1989 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Servier
- Registered trials
- 9, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Eye; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 5 | 0 | 1 |
| Phase 3 | 3 | 1 | 0 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2006 to now |